CN105030724A - Composition of anti-diabetic drugs - Google Patents
Composition of anti-diabetic drugs Download PDFInfo
- Publication number
- CN105030724A CN105030724A CN201510513797.XA CN201510513797A CN105030724A CN 105030724 A CN105030724 A CN 105030724A CN 201510513797 A CN201510513797 A CN 201510513797A CN 105030724 A CN105030724 A CN 105030724A
- Authority
- CN
- China
- Prior art keywords
- pioglitazone
- egelieting
- accounts
- capsule containing
- compound capsule
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicinal Preparation (AREA)
Abstract
The invention provides a composition of anti-diabetic drugs. The composition comprises alogliptin coated pellets, pioglitazone coated pellets and a gelatin capsule shell and is used for treating type II diabetes, wherein blank pellets comprise main drugs, filling agents and adhesives; in the total blank pellets, the main drugs account for 3-12wt%, the filling agents account for 20-60wt%, blank pellet cores account for 40-80wt% and the adhesives account for 1-10wt%; the weights gained by coating layers are about 2-10% of the weights of the drug-loaded blank pellets. Alogliptin and pioglitazone pellets with different coating colors are preferentially prepared. The composition has the advantages of simple and reliable production process, low loss, good product stability and few by-products, so that the composition is beneficial to large-scale industrial production.
Description
Technical field
The invention belongs to field of pharmaceutical preparations, specifically a kind of compound capsule containing Egelieting and pioglitazone.
Background technology
Diabetes are one group take hyperglycemia as the metabolic disease of feature caused by defect of insulin secretion and/or insulin action obstacle.Persistent high blood sugar and long-term metabolic are disorderly etc. can cause body tissue's organ, particularly eye, kidney, cardiovascular and neural infringement and dysfunction thereof and exhaustion.Severe patient can cause dehydration, the acute complications such as electrolyte disturbance and acid base imbalance ketoacidosis and Hyperosmotic coma.Diabetes are mainly divided into two types clinically, i.e. insulin-dependent (IDDM, I type) and non-insulin-depending type (NIDDM, II type).Wherein, type Ⅱdiabetes mellitus accounts for 90% ~ 95% of diabetics sum, its sickness rate is in the world in the trend increased year by year, especially gather way faster (estimating may increase by 170% in 2025) in developing country, become the chronic disease of the 3rd serious harm human health after tumor, cardiovascular and cerebrovascular disease.Current treatment means mainly changes lifestyles, blood sugar lowering and enhancing insulin sensitivity, antidiabetic medicine conventional clinically mainly contains insulin-glycosidase inhibitor, comprises biguanides, thiazolidinediones, sulfonylurea and non-sulfonylurea euglycemic agent etc.
Egelieting is DPP-4 (dipeptidyl peptidase-4) inhibitor, can promote the secretion of Postprandial insulin and the secretion of glucagon suppression, is applicable to treat type Ⅱdiabetes mellitus.The toleration of Egelieting is good, without dose-limiting toxicity, drug accumulation phenomenon is there is not when multiple dose administration, the infull patient of Liver and kidney function is also without the need to adjusting dosage and Pharmacokinetic Results also unable to take food thing impact, also do not find severely adverse event and dead case under study for action, do not have patient to drop by the wayside because of untoward reaction yet.
Pioglitazone is thiazolidinediones antidiabetic drug, by peroxide activator enzyme body paraphyte activated receptor-gamma, increases the expression of several genes encoding proteins and has and improve insulin resistant, promoting the effect of glycemic control; Do not increase islet β cell insulin simultaneously.Reduce inflammation in addition environment, reduce blood pressure, regulate the effects such as lipid metabolism and there is vascular protection effect.Be applicable to patients with NIDDM.
The principal character of type Ⅱdiabetes mellitus is that insulin resistant and islet beta cell function are disorderly, thus, is used alone above-mentioned any one medicine and all cannot reaches desirable glycemic control.The better effects if of coupling two medicine, but there is the problem of poor stability.
The compound tablet (trade name: Oseni) of Egelieting and pioglitazone is gone on the market in exploitation in 2011 by Japanese Takede Chemical Industries Ltd.Its patent information is disclosed in CN200880010374.4, the coated tablet of claimed above-mentioned compound preparation and multilayer tablet.Analyze embodiment visible pastille coatings proportion very large, this is be difficult to realize in process of production, and the uneven medicine that also can cause of coating rushes the problems such as leakage; And multilayer tablet still also exists the risk that two kinds of active ingredient contacts produce impurity.
Patent CN201220120673.7 discloses the tablet capsule of above-mentioned compound preparation, but is be difficult to realize for the tablet coating of column type.
Summary of the invention
The object of the invention is to the compound capsule containing Egelieting and pioglitazone.
The present invention is achieved through the following technical solutions:
The invention discloses a kind of compound capsule containing Egelieting and pioglitazone, described capsule forms primarily of the coated micropill of Egelieting, the coated micropill of pioglitazone and gelatine capsule shell.
As improving further, the coated micropill of Egelieting coated micropill of the present invention and pioglitazone by medicine carrying element ball and coatings composition, composition and content as follows:
As improving further, Egelieting of the present invention is Egelieting or its salt, and described pioglitazone is pioglitazone or its salt.
As improving further, the benzene sulfonate of the preferred Egelieting of Egelieting of the present invention, the hydrochlorate of the preferred pioglitazone of pioglitazone.
As improving further, medicine carrying element ball of the present invention is made up of principal agent, filler, celphere and binding agent, wherein, principal agent accounts for 3% ~ 12% of plain ball gross weight, filler accounts for 20% ~ 60%, and celphere accounts for 40% ~ 80%, and binding agent accounts for 1% ~ 10%.
As improving further, coatings of the present invention is made up of filmogen, plasticizer, antiplastering aid and coloring agent, wherein, filmogen accounts for 20% ~ 70% of coatings gross weight, plasticizer accounts for 2% ~ 40%, antiplastering aid accounts for 5% ~ 40%, and coloring agent accounts for 0% ~ 30%, and coatings weightening finish is about 2% ~ 10% of medicine carrying element ball weight.
As improving further, filler of the present invention is selected from one or more in lactose, mannitol, microcrystalline Cellulose and starch, celphere is selected from one or more the mixture in sucrose, starch and microcrystalline Cellulose, and binding agent is selected from one or more in water or alcohol be solvent polyvinylpyrrolidone, hydroxypropyl emthylcellulose, sodium carboxymethyl cellulose and hydroxypropyl cellulose.
As improving further, filler preferably microcrystalline cellulose of the present invention, preferable amount accounts for 30% ~ 45% of plain ball gross weight; Celphere preferably sucrose ball core.
As improving further, filmogen of the present invention is selected from one or more in hydroxypropyl emthylcellulose, polyvinyl alcohol, hydroxypropyl cellulose, plasticizer be selected from propylene glycol, Polyethylene Glycol, SA dibutyl ester one or more, antiplastering aid be selected from micropowder silica gel and Pulvis Talci one or more, coloring agent is preferably the coating of different colours.
As improving further, filmogen preferably polyethylene alcohol of the present invention, the preferred Polyethylene Glycol of plasticizer, antiplastering aid preferably talc powder.
Major advantage of the present invention is:
The compound capsule of Egelieting provided by the invention and pioglitazone, owing to respectively Egelieting and pioglitazone being prepared into coated micropill, effectively prevent the contact of two kinds of active component, place 3 months under 60 DEG C of conditions, the amount of the related substance derived by Egelieting maintains less than 0.04% all the time, the generation of by-product is avoided, improves the safety and stability of product.In addition, because two kinds of active component make micropill respectively and coating, therefore stripping is independent of each other, and in 10min, all stripping, more than 95%, ensure that the rapid release effect of product.And through 40 DEG C, place 3 months under 75%RH condition, the Dissolution behaviours of active component is not affected yet, and further ensure that the safety and stability of product.
Because two kinds of active component are made micropill by the present invention respectively, and carry out the coating of different colours, be thus more prone in the inspection and quality control of medicine; And the composition of this product is simple, preparation scheme is reliably easy, thus advantageously in industrialized great production.
Accompanying drawing explanation
Fig. 1 is the release profiles schematic diagram of Egelieting in the compound capsule of embodiment 1 to 9;
Fig. 2 is the release profiles schematic diagram of pioglitazone in the compound capsule of embodiment 1 to 9.
Detailed description of the invention
The invention discloses a kind of compound capsule containing Egelieting and pioglitazone, capsule forms primarily of the coated micropill of Egelieting, the coated micropill of pioglitazone and gelatine capsule shell.
Egelieting is Egelieting or its salt, comprises pharmacologically acceptable salt, the benzene sulfonate of preferred Egelieting, and pioglitazone is pioglitazone or its salt, comprises pharmacologically acceptable salt, preferred pioglitazone HCI salt.The coated micropill of Egelieting and pioglitazone is made up of medicine carrying element ball and coatings, and wherein medicine carrying element ball is made up of principal agent, filler, celphere and binding agent; Coatings is made up of filmogen, plasticizer, antiplastering aid and coloring agent.Wherein principal agent accounts for 3% ~ 12% of medicine carrying element ball gross weight, and filler accounts for 20% ~ 60%, and celphere accounts for 40% ~ 80%, and binding agent accounts for 1% ~ 10%; In coatings, filmogen accounts for 20% ~ 70% of coatings gross weight, and plasticizer accounts for 2% ~ 40%, and antiplastering aid accounts for 5% ~ 40%, and coloring agent accounts for 0% ~ 30%.Coatings weightening finish is about 2% ~ 10% of medicine carrying element ball weight.
Filler is selected from one or more in lactose, mannitol, microcrystalline Cellulose and starch; Celphere is selected from one or more the mixture in sucrose, starch and microcrystalline Cellulose; Binding agent is selected from one or more in water or alcohol be solvent polyvinylpyrrolidone, hydroxypropyl emthylcellulose, sodium carboxymethyl cellulose and hydroxypropyl cellulose; Filmogen is selected from one or more in hydroxypropyl emthylcellulose, polyvinyl alcohol, hydroxypropyl cellulose; Plasticizer be selected from propylene glycol, Polyethylene Glycol, SA dibutyl ester one or more; Antiplastering aid be selected from micropowder silica gel and Pulvis Talci one or more; Coloring agent is selected from iron oxide red, iron oxide yellow etc.
The preparation method of the compound capsule containing Egelieting and pioglitazone, comprises the following steps:
1) preparation of medicine carrying micropill: the Egelieting of recipe quantity or pioglitazone and filler are sieved respectively, mix homogeneously, prepares in centrifugal granulator with binding agent, namely obtains medicine carrying element ball by obtained micropill for 2 hours in 60 DEG C of dryings.Be dissolved in distilled water by the coating material of recipe quantity, mix homogeneously carries out coating in fluid bed, obtains coated micropill.
2) fill of coated micropill: utilize capsule filling machine to be filled in capsulae vacuus according to pharmaceutical capsules compatibility amount the coated micropill of above-mentioned Egelieting and pioglitazone, obtain the compound capsule of Egelieting and pioglitazone.
Below in conjunction with specific embodiment, set forth the present invention further.Should be understood that these embodiments are only not used in for illustration of the present invention to limit the scope of the invention.Unless otherwise indicated, otherwise all percent, ratio, ratio or number by weight.
(1) preparation of Egelieting coated micropill
Table 1 prepares the coated micropill (1000) of Egelieting respectively by prescription A, B and C
The Egelieting of recipe quantity, microcrystalline Cellulose are sieved respectively, mix homogeneously is that binding agent is prepared in centrifugal granulator with hydroxypropyl methylcellulose, namely obtained micropill is obtained the medicine carrying element ball of Egelieting for 2 hours in 60 DEG C of dryings.Be dissolved in distilled water by the coating material of recipe quantity, mix homogeneously carries out coating in fluid bed, obtains the coated micropill of Egelieting.
(2) preparation of pioglitazone coated micropill
Table 2 prepares the coated micropill (1000) of pioglitazone respectively by prescription D, E and F
The pioglitazone of recipe quantity, microcrystalline Cellulose are sieved respectively, mix homogeneously is that binding agent is prepared in centrifugal granulator with polyvidone, and namely obtained micropill obtains pioglitazone medicine carrying element ball for 2 hours in 60 DEG C of dryings.Be dissolved in distilled water by the coating material of recipe quantity, mix homogeneously carries out coating in fluid bed, obtains the coated micropill of pioglitazone.
Table 3 embodiment 1-9 combines Egelieting micropill that A, B and C prescription obtains and the obtained pioglitazone micropill of D, E and F prescription respectively, in the ratio fill of 1:1 in gelatine capsule.
The foregoing is only preferred embodiment of the present invention, not in order to limit the present invention, all any amendments done within the spirit and principles in the present invention, equivalent replacement and improvement etc., be all included within protection scope of the present invention.
Comparative example 1
Prepare the medicine carrying micropill of Egelieting and pioglitazone respectively by prescription B and prescription E, difference is not carry out coating.And in the ratio fill of 1:1 in gelatine capsule.
Comparative example 2
Contain the micropill of Egelieting and pioglitazone by following formula preparation simultaneously.
| Egelieting | 25g |
| Pioglitazone | 30g |
| Microcrystalline Cellulose | 180g |
| Celphere | 200g |
| Hydroxypropyl methylcellulose | 12g |
Test example 1
The compound recipe micropill of embodiment 1,5,9 and comparative example 1,2 is preserved 3 months with vial respectively under 60 DEG C of conditions, measures the amount of the related substances derived by Egelieting.
Table 4
| Embodiment 1 | Embodiment 5 | Embodiment 9 | Comparative example 1 | Comparative example 2 | |
| 0 month | <0.04％ | <0.04％ | <0.04％ | 0.06％ | 0.15％ |
| January | <0.04％ | <0.04％ | <0.04％ | 0.59％ | 1.18％ |
| February | <0.04％ | <0.04％ | 0.04％ | 1.10％ | 1.83％ |
| March | <0.04％ | <0.04％ | 0.04％ | 1.55％ | 2.10％ |
As shown in table 4, result shows that compound recipe pellet capsule of the present invention has good stability.
Test example 2
By paddle method (50rpm) 0.3M hydrochloric acid-potassium chloride buffer (37 DEG C, pH2.0, the Dissolution behaviours of Egelieting in the compound recipe pellet capsule of 900mL) Evaluation operation example 1,5,9 and comparative example 1,2, and (40 DEG C/75%RH) place the Dissolution behaviours after 3 months under acceleration environment, result is as shown in table 5.It is the average dissolution rate of 4 compound capsules shown in table.
Table 5
As shown in table 5, result shows that the Dissolution behaviours of compound recipe pellet capsule of the present invention Egelieting before and after preserving is all excellent.
Test example 3
By paddle method (50rpm) 0.3M hydrochloric acid-potassium chloride buffer (37 DEG C, pH2.0, the Dissolution behaviours of pioglitazone in the compound recipe pellet capsule of 900mL) Evaluation operation example 1,5,9 and comparative example 1,2, and (40 DEG C/75%RH) place the Dissolution behaviours after 3 months under acceleration environment, result is as shown in table 6.It is the average dissolution rate of 4 compound capsules shown in table.
Table 6
As shown in table 6, result shows that the Dissolution behaviours of compound recipe pellet capsule of the present invention pioglitazone before and after preserving is all excellent.
What more than exemplify is only the preferred embodiment of the present invention; the present invention is not limited to above embodiment; the oher improvements and changes that those skilled in the art directly derive without departing from the spirit and concept in the present invention or associate, all should think and be included in protection scope of the present invention.
Claims (10)
1. contain a compound capsule for Egelieting and pioglitazone, it is characterized in that, described capsule forms primarily of the coated micropill of Egelieting, the coated micropill of pioglitazone and gelatine capsule shell.
2. the compound capsule containing Egelieting and pioglitazone as claimed in claim 1, is characterized in that, the coated micropill of described Egelieting coated micropill and pioglitazone is by medicine carrying element ball and coatings composition.
3. the compound capsule containing Egelieting and pioglitazone as claimed in claim 1 or 2, it is characterized in that, described Egelieting is Egelieting or its salt, and described pioglitazone is pioglitazone or its salt.
4. the compound capsule containing Egelieting and pioglitazone as claimed in claim 3, is characterized in that, the benzene sulfonate of the preferred Egelieting of described Egelieting, the hydrochlorate of the preferred pioglitazone of described pioglitazone.
5. the compound capsule containing Egelieting and pioglitazone as described in claim 2 or 4, it is characterized in that, described medicine carrying element ball is made up of principal agent, filler, celphere and binding agent, wherein, principal agent accounts for 3% ~ 12% of plain ball gross weight, filler accounts for 20% ~ 60%, and celphere accounts for 40% ~ 80%, and binding agent accounts for 1% ~ 10%.
6. the compound capsule containing Egelieting and pioglitazone as described in claim 2 or 4, it is characterized in that, described coatings is made up of filmogen, plasticizer, antiplastering aid and coloring agent, wherein, filmogen accounts for 20% ~ 70% of coatings gross weight, and plasticizer accounts for 2% ~ 40%, and antiplastering aid accounts for 5% ~ 40%, coloring agent accounts for 0% ~ 30%, and coatings weightening finish is about 2% ~ 10% of medicine carrying element ball weight.
7. the compound capsule containing Egelieting and pioglitazone as claimed in claim 5, it is characterized in that, described filler is selected from one or more in lactose, mannitol, microcrystalline Cellulose and starch, described celphere is selected from one or more the mixture in sucrose, starch and microcrystalline Cellulose, and described binding agent is selected from one or more in water or alcohol be solvent polyvinylpyrrolidone, hydroxypropyl emthylcellulose, sodium carboxymethyl cellulose and hydroxypropyl cellulose.
8. the compound capsule containing Egelieting and pioglitazone as claimed in claim 7, it is characterized in that, described filler preferably microcrystalline cellulose, preferable amount accounts for 30% ~ 45% of plain ball gross weight; Described celphere preferably sucrose ball core.
9. the compound capsule containing Egelieting and pioglitazone as claimed in claim 6, it is characterized in that, described filmogen is selected from one or more in hydroxypropyl emthylcellulose, polyvinyl alcohol, hydroxypropyl cellulose, described plasticizer be selected from propylene glycol, Polyethylene Glycol, SA dibutyl ester one or more, described antiplastering aid be selected from micropowder silica gel and Pulvis Talci one or more, described coloring agent is iron oxide red or iron oxide yellow.
10. the compound capsule containing Egelieting and pioglitazone as claimed in claim 9, is characterized in that, described filmogen preferably polyethylene alcohol, the preferred Polyethylene Glycol of described plasticizer, described antiplastering aid preferably talc powder.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510513797.XA CN105030724A (en) | 2015-08-20 | 2015-08-20 | Composition of anti-diabetic drugs |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510513797.XA CN105030724A (en) | 2015-08-20 | 2015-08-20 | Composition of anti-diabetic drugs |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105030724A true CN105030724A (en) | 2015-11-11 |
Family
ID=54438096
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510513797.XA Pending CN105030724A (en) | 2015-08-20 | 2015-08-20 | Composition of anti-diabetic drugs |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105030724A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108096227A (en) * | 2018-01-25 | 2018-06-01 | 河北科技大学 | The molten film preparation in Egelieting oral cavity |
| EP4023217A1 (en) * | 2020-12-31 | 2022-07-06 | Sanovel Ilac Sanayi ve Ticaret A.S. | Pharmaceutical capsule compositions of alogliptine |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010147768A1 (en) * | 2009-06-15 | 2010-12-23 | Merck Sharp & Dohme Corp. | Pharmaceutical compositions of combinations of dipeptidyl peptidase-4 inhibitors with pioglitazone |
| CN102573476A (en) * | 2009-10-23 | 2012-07-11 | 默沙东公司 | Pharmaceutical compositions of combinations of dipeptidyl peptidase-4 inhibitors with pioglitazone |
| CN103356621A (en) * | 2012-03-28 | 2013-10-23 | 黑龙江福和华星制药集团股份有限公司 | Novel capsule filled with alogliptin solid preparation and pioglitazone solid preparation |
| CN103446063A (en) * | 2013-08-26 | 2013-12-18 | 中国人民解放军第150中心医院 | Assembly method and preparation technology of compound metformin hydrochloride and pioglitazone hydrochloride slow-release micro-pellet preparation |
| CN103446062A (en) * | 2013-08-26 | 2013-12-18 | 中国人民解放军第150中心医院 | Preparing method of compound metformin hydrochloride and pioglitazone hydrochloride slow-release micro-pellet preparation |
| WO2015071889A1 (en) * | 2013-11-18 | 2015-05-21 | Ranbaxy Laboratories Limited | Oral compositions of saxagliptin |
-
2015
- 2015-08-20 CN CN201510513797.XA patent/CN105030724A/en active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010147768A1 (en) * | 2009-06-15 | 2010-12-23 | Merck Sharp & Dohme Corp. | Pharmaceutical compositions of combinations of dipeptidyl peptidase-4 inhibitors with pioglitazone |
| CN102573476A (en) * | 2009-10-23 | 2012-07-11 | 默沙东公司 | Pharmaceutical compositions of combinations of dipeptidyl peptidase-4 inhibitors with pioglitazone |
| CN103356621A (en) * | 2012-03-28 | 2013-10-23 | 黑龙江福和华星制药集团股份有限公司 | Novel capsule filled with alogliptin solid preparation and pioglitazone solid preparation |
| CN103446063A (en) * | 2013-08-26 | 2013-12-18 | 中国人民解放军第150中心医院 | Assembly method and preparation technology of compound metformin hydrochloride and pioglitazone hydrochloride slow-release micro-pellet preparation |
| CN103446062A (en) * | 2013-08-26 | 2013-12-18 | 中国人民解放军第150中心医院 | Preparing method of compound metformin hydrochloride and pioglitazone hydrochloride slow-release micro-pellet preparation |
| WO2015071889A1 (en) * | 2013-11-18 | 2015-05-21 | Ranbaxy Laboratories Limited | Oral compositions of saxagliptin |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108096227A (en) * | 2018-01-25 | 2018-06-01 | 河北科技大学 | The molten film preparation in Egelieting oral cavity |
| EP4023217A1 (en) * | 2020-12-31 | 2022-07-06 | Sanovel Ilac Sanayi ve Ticaret A.S. | Pharmaceutical capsule compositions of alogliptine |
| WO2022146355A3 (en) * | 2020-12-31 | 2022-08-04 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | Pharmaceutical capsule compositions of alogliptine |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2029112B1 (en) | Pharmaceutical composition comprising hydrochlorothiazide and telmisartan | |
| US11903908B2 (en) | Methods of administering amantadine | |
| CN106924208A (en) | A kind of compound Dapagliflozin Metformin Extended-release Tablets and preparation method thereof | |
| KR20160111237A (en) | An oral composite formulation containing metformin and sitagliptin | |
| KR20100059912A (en) | Pharmaceutical combination of aliskiren and valsartan | |
| US20150283248A1 (en) | Pharmaceutical compositions of Linagliptin and process for preparation thereof | |
| CN102908331A (en) | Duloxetine hydrochloride enteric capsules and preparation method thereof | |
| EP3364955B1 (en) | Pharmaceutical formulation | |
| CN105030724A (en) | Composition of anti-diabetic drugs | |
| CN103417496A (en) | Method for preparing metformin hydrochloride controlled-release pellet preparation | |
| CN112402392A (en) | Dabigatran etexilate mesylate sustained release preparation and preparation method thereof | |
| EP3025707A1 (en) | A multilayer tablet comprising metformin and pioglitazone | |
| JP5671767B2 (en) | Oral preparation containing metformin and α-glycosidase inhibitor, and method for producing the same | |
| US10314794B2 (en) | Metoprolol sustained-release composition and preparation method thereof | |
| JP2018016622A (en) | Duloxetine-containing pharmaceutical composition | |
| CN106620715A (en) | Drug composition for treating diabetes and preparation method of drug composition | |
| CN107913259A (en) | A kind of Metformin hydrochloride controlled release tablet and preparation method thereof | |
| EP2531180B1 (en) | Oral complex composition comprising pseudoephedrine and levocetirizine | |
| CN101168059A (en) | Stable medicinal composition containing biguanide, sulfonylurea and thiazolidinedione and preparation method thereof | |
| CN103446062A (en) | Preparing method of compound metformin hydrochloride and pioglitazone hydrochloride slow-release micro-pellet preparation | |
| CN103432129B (en) | A kind of compound formulation of pioglitazone hydrochloride sustained-release pellet preparations | |
| US20090175934A1 (en) | Extended Release Pharmaceutical Formulation of Venlafaxine and Method of Manufacturing the Same | |
| CN102988324A (en) | Preparation for glipizide compression-coated controlled-release tablets | |
| CN111643506B (en) | A kind of olanzapine and fluoxetine compound capsule preparation and preparation method thereof | |
| CN103417495A (en) | Method for preparing pioglitazone hydrochloride controlled-release pellet preparation slow-release layer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20151111 |
|
| RJ01 | Rejection of invention patent application after publication |